Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toremifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 9/20 | 0.80 |
| ▸ | ESR2 known ✓ | Q92731 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | THPO | P40225 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toremifene SCHEMBL4564 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL15576158 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL177941 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL30053819 | 1.00 | ESR1 (0.80) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL21464516 | 0.96 | ESR1 (0.87) | ESR1LMNAESR2MEN1TP53 | |
| Toremifene SCHEMBL15865397 | 0.89 | ESR1 (0.67) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL4019370 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL5328781 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL10336277 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 | |
| Tamoxifen SCHEMBL17164701 | 0.89 | ESR1 (1.00) | ESR1LMNAESR2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427812-A2 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents of the University of Michigan (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3439640-B1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | CLEVELAND CLINIC FOUND (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3471712-B1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3125884-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3131544-B1 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-2911748-B1 | CANCER STEM CELL VACCINATION AND TREATMENT | UNIV MICHIGAN REGENTS (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2831067-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9745314-B2 | MDM2 inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-29 | — | — | US | disclosed |
| EP-1718767-B1 | COMPOSITIONS FOR TREATING BREAST AND PANCREATIC CANCER | UNIV MICHIGAN (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2369014-A1 | Compositions and methods for characterizing, regulating, diagnosing and treating cancer | The Regents Of The University Of Michigan Office Of Technology Transfer (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2141173-A1 | Methods and compositions for the inhibition of gene expression | Pronai Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-6458848-B1 | ADMINISTERING TO A PATIENT SUFFERING FORM AUTOIMMUNE SIALADENITIS OR SJOGREN'S DISEASE (AUTOIMMUNE DISEASES) TOREMIFENE OR A SALT | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-10-01 | — | — | US | disclosed |
| US-20020107231-A1 | Remedy for autoimmune diseases | ITOH JUNPEI (US) | 2002-08-08 | — | — | US | disclosed |
| US-6387958-B1 | ADMINISTERING A DOSAGE OF TOREMIFENE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-05-14 | — | — | US | disclosed |
| US-6355688-B1 | ADMINISTERING TOREMIFENE CITRATE | ITOH JUNPEI (US) | 2002-03-12 | — | — | US | disclosed |
| US-6184253-B1 | TREATING WITH TOREMIFENE OR SALT | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0667768-B1 | USE OF TOREMIFENE FOR TREATING SLE | NIPPON KAYAKU KK (JP) | 1999-03-03 | — | — | EP | disclosed |
| EP-0776661-A1 | Combined preparation of antiestrogen and glucocorticoid for the treatment of autoimmune disease | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-06-04 | — | — | EP | disclosed |